Cargando…
PBF509, an Adenosine A(2A) Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders
Adenosine A(2A) receptor (A(2A)R) antagonists have emerged as complementary non-dopaminergic drugs to alleviate Parkinson’s disease (PD) symptomatology. Here, we characterize a novel non-xhantine non-furan A(2A)R antagonist, PBF509, as a potential pro-dopaminergic drug for PD management. First, PBF5...
Autores principales: | Núñez, Fabiana, Taura, Jaume, Camacho, Juan, López-Cano, Marc, Fernández-Dueñas, Víctor, Castro, Naomi, Castro, Julio, Ciruela, Francisco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202948/ https://www.ncbi.nlm.nih.gov/pubmed/30405415 http://dx.doi.org/10.3389/fphar.2018.01200 |
Ejemplares similares
-
Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder
por: Massari, Caio M., et al.
Publicado: (2017) -
Striatal Dopamine D(2)-Muscarinic Acetylcholine M(1) Receptor–Receptor Interaction in a Model of Movement Disorders
por: Crans, René A. J., et al.
Publicado: (2020) -
Corrigendum: Striatal dopamine D2-muscarinic acetylcholine M1 receptor-receptor interaction in a model of movement disorders
por: Crans, René A. J., et al.
Publicado: (2022) -
Uncovering Caffeine’s Adenosine A(2A) Receptor Inverse Agonism in Experimental Parkinsonism
por: Fernández-Dueñas, Víctor, et al.
Publicado: (2014) -
Untangling dopamine-adenosine receptor-receptor assembly in experimental parkinsonism in rats
por: Fernández-Dueñas, Víctor, et al.
Publicado: (2015)